Caribou Biosciences, Inc. Common Stock (CRBU) — Analysis Summary
Caribou Biosciences, Inc. Common Stock (CRBU) has a market cap of $178.53M with year-over-year revenue growth of +11.7%. Net margin stands at -1327.4%. The stock trades at a P/E ratio of -1.3.
Key Takeaways
- Revenue changed +11.7% year-over-year
- Net margin of -1327.4%
- P/E ratio of -1.3
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, CRBU posted revenue growth of +11.7% and trades at a P/E of -1.3.
Caribou Biosciences, Inc. Common Stock (CRBU)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -1175.7% — severe operating losses
Net margin at -1189.1% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
97
Headquarters
BERKELEY, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.